Loading...
menu
Search
Features
Markets
News
Resources
Pricing
Home
ETF
NRSN
NRSN
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
Latest NRSN ETF News Today | Earnings, Events & Price Alerts
NRSN News
NeuroSense Releases New ALS Treatment Data
Feb 18 2026
PRnewswire
NeuroSense Secures Australian Patent, Strengthening Global IP for PrimeC
Feb 09 2026
PRnewswire
NeuroSense Therapeutics Secures U.S. Patent for PrimeC Alzheimer’s Therapy Valid Through 2043
Jan 21 2026
seekingalpha
NeuroSense Secures U.S. Patent for PrimeC Combination in Alzheimer's Treatment
Jan 21 2026
PRnewswire
NeuroSense Appoints Alzheimer's Expert Prof. Arnold to Advance PrimeC Development
Jan 08 2026
PRnewswire
Galectin Secures $10M Credit Line, FDA Provides Guidance on Regulatory Pathway
Dec 26 2025
NASDAQ.COM
NeuroSense Completes Safety Analysis of PrimeC for Alzheimer's with Favorable Data
Dec 23 2025
NASDAQ.COM
NeuroSense Completes Safety Analysis of PrimeC in Alzheimer's Phase 2 Study
Dec 22 2025
PRnewswire
NeuroSense Resumes Regulatory Progress for PrimeC in Canada, Anticipates NDS Submission by Mid-2026
Dec 04 2025
PRnewswire
D. Boral Capital Reiterates Buy Rating for NeuroSense Therapeutics with $14 Price Target Intact
Nov 24 2025
Benzinga
NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS
Nov 24 2025
PRnewswire
NeuroSense to Host Investor Webinar on December 8, 2025
Nov 03 2025
PRnewswire
NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons
Sep 10 2025
PRnewswire
D. Boral Capital Maintains Buy on NeuroSense Therapeutics, Maintains $14 Price Target
Aug 15 2025
Benzinga
NeuroSense Provides Business Update and Progress for the First Half of 2025
Aug 01 2025
PRnewswire
Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights
May 12 2025
Benzinga
Show More News
